Overview

Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome

Status:
Completed

Trial end date:
2016-11-01

Target enrollment:

Participant gender:

Summary

Metformin is the first-line therapy for PCOS with high metabolic risk, yet a large proportion of patients cannot tolerate it due to associated gastrointestinal adverse events. The alternative pharmacological strategy when metformin cannot be tolerated is not well established in this population. Our aim was to evaluate whether sitagliptin (SITA) preserves metabolic profile in metformin (MET) intolerant PCOS with high metabolic risk.

Phase:

Phase 4

Details

Lead Sponsor:

University Medical Centre Ljubljana

Treatments:

Dipeptidyl-Peptidase IV Inhibitors
Metformin
Sitagliptin Phosphate